Michael Gelband’s Covetrus, Inc. Common Stock CVET Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-36,954
Closed -$772K 2318
2022
Q3
$772K Buy
+36,954
New +$769K 0.01% 1210
2022
Q2
Sell
-88,404
Closed -$1.48M 2724
2022
Q1
$1.48M Buy
+88,404
New +$1.55M 0.02% 924
2021
Q4
Sell
-36,248
Closed -$658K 2767
2021
Q3
$658K Buy
+36,248
New +$831K 0.01% 1243
2021
Q2
Sell
-27,245
Closed -$817K 2998
2021
Q1
$817K Sell
27,245
-3,453
-11% -$118K 0.01% 1041
2020
Q4
$882K Buy
30,698
+21,004
+217% +$567K 0.01% 927
2020
Q3
$237K Sell
9,694
-21,290
-69% -$459K ﹤0.01% 1399
2020
Q2
$554K Buy
30,984
+17,372
+128% +$228K 0.01% 1028
2020
Q1
$111K Buy
+13,612
New +$156K 0.01% 880
2019
Q4
Sell
-15,000
Closed -$178K 1998
2019
Q3
$178K Buy
+15,000
New +$278K 0.01% 1153

Other funds holding CVET

Michael Gelband's CVET Position: Q4 2022 in Review

Michael Gelband sold out of Covetrus, Inc. Common Stock (CVET) in Q4 2022, closing a stake of 36,954 shares — an estimated $772K sold.

Michael Gelband first reported a position in CVET in Q3 2019 and held it in 9 quarters. The position peaked at $1.48M in Q1 2022. 5 funds tracked by Wall St. Rank hold CVET as of Q4 2022.

  • Michael Gelband reported no remaining Covetrus, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Michael Gelband sold 36,954 Covetrus, Inc. Common Stock shares in Q4 2022, an estimated $772K.
  • Michael Gelband first reported a position in Covetrus, Inc. Common Stock in Q3 2019 and held it in 9 quarters.
  • Michael Gelband's Covetrus, Inc. Common Stock position peaked at $1.48M in Q1 2022.
  • 5 funds tracked by Wall St. Rank held Covetrus, Inc. Common Stock as of Q4 2022.

Based on ExodusPoint Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.